SCZD2
MCID: SCH085
MIFTS: 45

Schizophrenia 2 (SCZD2)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 2

MalaCards integrated aliases for Schizophrenia 2:

Name: Schizophrenia 2 57 12 74 15 72
Sczd2 57 12 74
Schizophrenia Susceptibility Locus, Chromosome 11q-Related 57
Schizophrenia Susceptibility Locus Chromosome 11q-Related 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0070078
OMIM 57 603342
MeSH 44 D012559
MedGen 42 C1864010
UMLS 72 C1864010

Summaries for Schizophrenia 2

UniProtKB/Swiss-Prot : 74 Schizophrenia 2: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Schizophrenia 2, also known as sczd2, is related to schizophrenia 1 and schizophrenia. An important gene associated with Schizophrenia 2 is SCZD2 (Schizophrenia Disorder 2), and among its related pathways/superpathways are Ras signaling pathway and Development HGF signaling pathway. The drugs Zinc and insulin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A schizophrenia that has material basis in an autosomal dominant mutation of SCZD2 on chromosome 11q14-q21.

More information from OMIM: 603342

Related Diseases for Schizophrenia 2

Diseases in the Schizophrenia family:

Schizophrenia 1 Schizophrenia 3
Schizophrenia 4 Schizophrenia 6
Schizophrenia 5 Schizophrenia 7
Schizophrenia 8 Schizophrenia 2
Schizophrenia 9 Schizophrenia 10
Schizophrenia 11 Schizophrenia 12
Schizophrenia 14 Schizophrenia 13
Schizophrenia 15 Schizophrenia 16
Schizophrenia 18 Schizophrenia 19
Early-Onset Schizophrenia

Diseases related to Schizophrenia 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 1 29.5 TSNAX-DISC1 DISC1
2 schizophrenia 29.2 TSNAX-DISC1 SCZD2 NTF3 DISC2 DISC1 BDNF
3 hypochondriasis 10.4 NTF4 NTF3
4 diabetic autonomic neuropathy 10.1 NTF3 NGF
5 diabetic polyneuropathy 10.1 NTF3 NGF
6 schizoaffective disorder 10.0 DISC2 DISC1 BDNF
7 simultanagnosia 10.0 MFGE8 APOE
8 mood disorder 10.0 DISC2 DISC1 BDNF
9 cannabis abuse 9.9 NGF BDNF
10 senile plaque formation 9.9 CHAT APOE
11 neuropathy, hereditary sensory and autonomic, type v 9.9 NGF BDNF
12 adult astrocytic tumour 9.9 NGF BDNF
13 head injury 9.8 CHAT APOE
14 paine syndrome 9.8 NGF BDNF
15 tendinosis 9.7 CHAT BDNF
16 bipolar disorder 9.7 NTF3 DISC2 DISC1 BDNF
17 major affective disorder 1 9.7
18 tardive dyskinesia 9.7
19 psychotic disorder 9.7
20 drug-induced hearing loss 9.7 HRK BDNF
21 hermansky-pudlak syndrome 3 9.6 TYR APOE
22 traumatic brain injury 9.5 BDNF APOE
23 disease of mental health 9.4 DISC1 BDNF APOE
24 ocular dominance 9.3 NTF3 NGF CHAT BDNF
25 major depressive disorder 9.2 DISC2 DISC1 BDNF APOE
26 hydrocephalus 9.1 NTF3 NGF FLNA APOE
27 schizophrenia 3 9.1 NGF MFGE8 HRK APOE
28 nervous system disease 8.9 NGF CHAT BDNF APOE
29 central nervous system disease 8.9 NGF CHAT BDNF APOE
30 parkinson disease, late-onset 8.8 NGF CHAT BDNF APOE

Graphical network of the top 20 diseases related to Schizophrenia 2:



Diseases related to Schizophrenia 2

Symptoms & Phenotypes for Schizophrenia 2

Clinical features from OMIM:

603342

MGI Mouse Phenotypes related to Schizophrenia 2:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 APOE BDNF CHAT DISC1 FLNA NGF
2 growth/size/body region MP:0005378 9.96 APOE BDNF CHAT DISC1 FLNA NGF
3 cardiovascular system MP:0005385 9.92 APOE CHAT FLNA MFGE8 NGF NTF3
4 nervous system MP:0003631 9.85 APOE BDNF CHAT DISC1 FLNA NGF
5 reproductive system MP:0005389 9.56 APOE BDNF CHAT FLNA MFGE8 NTF3
6 vision/eye MP:0005391 9.17 APOE BDNF CHAT FLNA NGF NTF3

Drugs & Therapeutics for Schizophrenia 2

Drugs for Schizophrenia 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2 insulin Phase 4
3 Insulin, Globin Zinc Phase 4
4 Hypoglycemic Agents Phase 4
5
Fluphenazine Approved Phase 3 69-23-8 3372
6
Cariprazine Approved, Investigational Phase 3 839712-12-8 11154555
7
Clozapine Approved Phase 3 5786-21-0 2818
8
Kynurenic acid Investigational Phase 2, Phase 3 492-27-3 3845
9 Omega 3 Fatty Acid Phase 2, Phase 3
10 Quetiapine Fumarate Phase 3 111974-72-2
11 Fluphenazine depot Phase 3
12 Fluphenazine enanthate Phase 3
13 Antidepressive Agents Phase 2, Phase 3
14 Antidepressive Agents, Second-Generation Phase 2, Phase 3
15 Tryptophan Phase 2, Phase 3
16 Tranquilizing Agents Phase 3
17 Serotonin Antagonists Phase 3
18 Central Nervous System Depressants Phase 3
19 Serotonin Agents Phase 3
20 Antipsychotic Agents Phase 3
21 Psychotropic Drugs Phase 3
22 GABA Agents Phase 3
23 Adrenergic Agents Phase 3
24 Neurotransmitter Uptake Inhibitors Phase 3
25 Atomoxetine Hydrochloride Phase 3
26
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
27
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
28
Galantamine Approved Phase 2 357-70-0 9651
29
Levodopa Approved Phase 2 59-92-7 6047
30
Carbidopa Approved Phase 2 28860-95-9 34359
31
Icodextrin Approved, Investigational Phase 2 337376-15-5
32
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
33
Polyestradiol phosphate Approved Phase 2 28014-46-2
34 Oxytocics Phase 2
35 Cholinesterase Inhibitors Phase 2
36 Peripheral Nervous System Agents Phase 2
37 Nootropic Agents Phase 2
38 Autonomic Agents Phase 2
39 Dihydroxyphenylalanine Phase 2
40 Adjuvants, Immunologic Phase 2
41 Antiparkinson Agents Phase 2
42 Carbidopa, levodopa drug combination Phase 2
43 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2
44 Immunologic Factors Phase 2
45 Estrogens Phase 2
46 Contraceptive Agents Phase 2
47 Hormones Phase 2
48 Estradiol 17 beta-cypionate Phase 2
49 Hormone Antagonists Phase 2
50 Estradiol 3-benzoate Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Intranasal Insulin Treatment in Patients With Schizophrenia Completed NCT00575666 Phase 4 Insulin or Placebo
2 A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine Active, not recruiting NCT02286206 Phase 4 Clozapine
3 Safety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial Withdrawn NCT00702793 Phase 4 Varenicline
4 Ethyl-EPA Treatment of Prodromal Patients Completed NCT00634361 Phase 2, Phase 3 ethyl-eicosapentaenoic acid
5 New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia Completed NCT00161018 Phase 3 Quetiapine, Risperidone, Fluphenazine
6 A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia Recruiting NCT03593213 Phase 3 Cariprazine;Placebo
7 Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls Recruiting NCT02067975 Phase 2, Phase 3 Tryptophan;Placebo
8 Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study) Terminated NCT00216281 Phase 3 Clozapine augmented with atomoxetine up to 40 mg or placebo
9 Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study to Compare the Effectiveness of Brexpiprazole to That of Risperidone in Adult Patients With Schizophrenia Withdrawn NCT02758067 Phase 3 brexpiprazole;risperidone
10 A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder Unknown status NCT01598623 Phase 2 Oxytocin
11 Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia Completed NCT01012167 Phase 2 Oxytocin;Galantamine
12 Augmentation of Antipsychotics With L-Dopa (Sinemet) Completed NCT01636037 Phase 2 levodopa/carbidopa (generic version of Sinemet)
13 Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia Completed NCT00357006 Phase 2 Estradiol;Estradiol
14 Relationships of One-carbon Cycle Pathway With Psychopathology and Metabolic Abnormalities in Patients With Schizophrenia and Potential Intervention Strategy With Folic Acid and Vitamin B12 Unknown status NCT02916121
15 Shiatsu Adjuvant Therapy And Placebo For Schizophrenia:a Double Blind Study Unknown status NCT00788970
16 Dialectical Behavioral Therapy (DBT) Based Skills Group for Children With Emotional Dysregulation and Their Parents Unknown status NCT01299740
17 A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES) Unknown status NCT00173069
18 Art Therapy for Symptom Reduction in Acute Schizophrenia - a Randomised Controlled Trial (Kunsttherapie Zur Symptomreduktion Bei Akuter Schizophrenie - Eine Randomisierte Kontrollierte Pilotstudie) Completed NCT01622166
19 Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia Completed NCT01587521
20 Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia Completed NCT02568709 Early Phase 1 Oxytocin;Saline Nasal Spray
21 The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong: an Open Label Randomized Controlled Trial Completed NCT02435784
22 Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia Completed NCT00770237
23 2-Way Pagers to Improve Schizophrenia Medication Adherence Completed NCT00392236
24 Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia Completed NCT02775864 Antipsychotic;Antidepressant;Benzodiazepine;Mood stabilizer
25 The Impact of Yoga Supplementation on Cognitive Function Among Indian Outpatients With Schizophrenia Completed NCT01879709
26 Implementing Patient-Centered Decision Support for Mental Health Completed NCT02183844
27 Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence Completed NCT01037075
28 Brain Circuits in Schizophrenia and Smoking Completed NCT01369966
29 Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects Completed NCT02575209
30 Implementing Effective, Collaborative Care for Schizophrenia Completed NCT00137280
31 A 12-weeks Study to Evaluate the Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of First Episode Schizophrenia Recruiting NCT03379597 Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
32 Effect of rTMS Over the Medial Cerebellum on Negative Symptoms and Cognitive Dysmetria in Subjects With Treatment Refractory Schizophrenia Recruiting NCT02242578
33 Cognitive Remediation for Perceptual Deficits in Schizophrenia Active, not recruiting NCT02337439
34 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms on Schizophrenia: Controlled, Randomised, Double Blind Trial Not yet recruiting NCT03284138

Search NIH Clinical Center for Schizophrenia 2

Genetic Tests for Schizophrenia 2

Anatomical Context for Schizophrenia 2

MalaCards organs/tissues related to Schizophrenia 2:

41
Brain, Testes, Cortex, Cerebellum, Prefrontal Cortex, Eye, Placenta

Publications for Schizophrenia 2

Articles related to Schizophrenia 2:

(show top 50) (show all 223)
# Title Authors PMID Year
1
Schizophrenia-associated chromosome 11q21 translocation: identification of flanking markers and development of chromosome 11q fragment hybrids as cloning and mapping resources. 38 8
8383424 1993
2
A genetic association study of chromosome 11q22-24 in two different samples implicates the FXYD6 gene, encoding phosphohippolin, in susceptibility to schizophrenia. 8
17357072 2007
3
Family-based association study of schizophrenia with 444 markers and analysis of a new susceptibility locus mapped to 11q13.3. 8
15108173 2004
4
Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. 8
11179014 2001
5
Genome scan of schizophrenia. 8
9619145 1998
6
Physical mapping of a glutamate receptor gene in relation to a balanced translocation associated with schizophrenia in a large Scottish family. 8
9460801 1997
7
An allelic association study of two polymorphic markers in close proximity to a balanced translocation t(1:11) that co-segregates with mental illness. 8
9460802 1997
8
Linkage results on 11Q21-22 in Eastern Quebec pedigrees densely affected by schizophrenia. 8
8825888 1995
9
A contiguous clone map over 3 Mb on the long arm of chromosome 11 across a balanced translocation associated with schizophrenia. 8
7490076 1995
10
Exclusion of linkage of schizophrenia to the gene for the dopamine D2 receptor (DRD2) and chromosome 11q translocation sites. 8
7480434 1995
11
Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. 8
7485242 1995
12
Direct microdissection and microcloning of a translocation breakpoint region, t(1;11)(q42.2;q21), associated with schizophrenia. 8
7736785 1995
13
Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. 8
8439241 1993
14
A linkage study of chromosome 11q in schizophrenia. 8
8439242 1993
15
Association within a family of a balanced autosomal translocation with major mental illness. 8
1973210 1990
16
A balanced chromosomal translocation partially co-segregating with psychotic illness in a family. 8
2349309 1990
17
HIV, schizophrenia, and all-cause mortality: A population-based cohort study of individuals accessing universal medical care from 1998 to 2012 in British Columbia, Canada. 38
31255392 2019
18
International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. 38
31054641 2019
19
Mental illness stigma among Pacific Islanders. 38
30716597 2019
20
Mental health multimorbidity and poor quality of life in patients with schizophrenia. 38
29709490 2018
21
Associations among domains of self-disturbance in schizophrenia. 38
29913377 2018
22
A review of impaired visual processing and the daily visual world in patients with schizophrenia. 38
30214081 2018
23
Schizophrenia as Potential Trigger for Melanoma Development and Progression! The Psycho-Neuro-Endocrine-Oncology (P.N.E.O) Network! 38
30159073 2018
24
Abnormal brain activation during threatening face processing in schizophrenia: A meta-analysis of functional neuroimaging studies. 38
29153447 2018
25
Multinational comparative cross-sectional survey of views of medical students about acceptable terminology and subgroups in schizophrenia. 38
29880569 2018
26
Electroretinographic anomalies in schizophrenia. 38
29745706 2018
27
Abdominal Vagal Afferents Modulate the Brain Transcriptome and Behaviors Relevant to Schizophrenia. 38
29326171 2018
28
Imaging Violence in Schizophrenia: A Systematic Review and Critical Discussion of the MRI Literature. 38
30083111 2018
29
Sex and Diffusion Tensor Imaging of White Matter in Schizophrenia: A Systematic Review Plus Meta-analysis of the Corpus Callosum. 38
28449132 2018
30
Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders. 38
29796036 2018
31
Comorbid Diagnosis of Psychotic Disorders in Borderline Personality Disorder: Prevalence and Influence on Outcome. 38
29593589 2018
32
Exome Sequencing Identifies TENM4 as a Novel Candidate Gene for Schizophrenia in the SCZD2 Locus at 11q14-21. 38
30745909 2018
33
Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. 38
28980344 2017
34
Guidelines for the Pharmacotherapy of Schizophrenia in Adults. 38
28703015 2017
35
Identification of the delivery of cognitive behavioural therapy for psychosis (CBTp) using a cross-sectional sample from electronic health records and open-text information in a large UK-based mental health case register. 38
28716789 2017
36
The role of shame in people with a diagnosis of schizophrenia. 38
28105670 2017
37
Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia. 38
27455897 2017
38
Schizophrenia Associated with Epileptiform Discharges without Seizures Successfully Treated with Levetiracetam. 38
28228737 2017
39
Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. 38
27926742 2017
40
Schizophrenia and sleep disorders: links, risks, and management challenges. 38
29033618 2017
41
Aberrant intra-salience network dynamic functional connectivity impairs large-scale network interactions in schizophrenia. 38
27825906 2016
42
What are the top 10 physical activity research questions in schizophrenia? 38
26728764 2016
43
Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia. 38
26630458 2016
44
Cognitive remediation in schizophrenia: A methodological appraisal of systematic reviews and meta-analyses. 38
26828372 2016
45
The search for new biomarkers for cognition in schizophrenia. 38
29114461 2015
46
Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia. 38
26647865 2015
47
New Targets for Prevention of Schizophrenia: Is It Time for Interventions in the Premorbid Phase? 38
25925393 2015
48
Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. 38
25863358 2015
49
An eye-tracking investigation of intentional motion perception in patients with schizophrenia. 38
25247443 2015
50
How connected are people with schizophrenia? Cell phone, computer, email, and social media use. 38
25563669 2015

Variations for Schizophrenia 2

Expression for Schizophrenia 2

Search GEO for disease gene expression data for Schizophrenia 2.

Pathways for Schizophrenia 2

Pathways related to Schizophrenia 2 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 NTF4 NTF3 NGF BDNF
2
Show member pathways
12.44 NTF4 NTF3 NGF BDNF
3 12.43 NTF4 NTF3 NGF FLNA BDNF
4
Show member pathways
12.42 NTF4 NTF3 NGF BDNF
5
Show member pathways
12.28 NTF4 NTF3 NGF FLNA BDNF
6
Show member pathways
12.15 NTF4 NTF3 NGF BDNF
7
Show member pathways
11.94 NTF4 NTF3 NGF BDNF
8 11.91 NGF CHAT BDNF
9 11.81 NTF3 NGF BDNF
10
Show member pathways
11.77 NTF4 NTF3 NGF BDNF
11 11.4 NTF4 NTF3 NGF BDNF
12
Show member pathways
11.28 NTF4 NTF3 NGF BDNF
13 11.09 NTF3 NGF BDNF
14
Show member pathways
11.04 NTF4 NTF3 NGF BDNF
15 10.92 NTF4 NTF3 NGF CHAT BDNF

GO Terms for Schizophrenia 2

Cellular components related to Schizophrenia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.46 NTF4 NTF3 NGF BDNF
2 dendrite GO:0030425 9.35 NTF4 NTF3 NGF BDNF APOE
3 synaptic vesicle GO:0008021 8.92 NTF4 NTF3 NGF BDNF

Biological processes related to Schizophrenia 2 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.78 NTF4 NTF3 NGF BDNF
2 memory GO:0007613 9.73 NTF4 NTF3 NGF BDNF
3 negative regulation of neuron apoptotic process GO:0043524 9.72 NTF4 NTF3 NGF BDNF APOE
4 neuron projection morphogenesis GO:0048812 9.71 NTF4 NTF3 NGF BDNF
5 modulation of chemical synaptic transmission GO:0050804 9.67 NTF4 NTF3 NGF BDNF
6 neurotrophin TRK receptor signaling pathway GO:0048011 9.63 NTF4 NGF BDNF
7 regulation of neuron differentiation GO:0045664 9.56 NTF4 NTF3 NGF BDNF
8 long-term memory GO:0007616 9.52 NTF4 APOE
9 activation of phospholipase C activity GO:0007202 9.51 NTF4 BDNF
10 positive regulation of collateral sprouting GO:0048672 9.49 NGF BDNF
11 peripheral nervous system development GO:0007422 9.46 NTF4 NTF3 NGF BDNF
12 nerve development GO:0021675 9.26 NTF4 NTF3 NGF BDNF
13 nerve growth factor signaling pathway GO:0038180 8.92 NTF4 NTF3 NGF BDNF

Molecular functions related to Schizophrenia 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.92 NTF4 NTF3 NGF BDNF

Sources for Schizophrenia 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....